RAFAEL HOLDINGS, INC. Cost, Depreciation, Amortization and Depletion
RAFAEL HOLDINGS, INC. (RFL) reported Cost, Depreciation, Amortization and Depletion of $48.00 thousand for the 3-month period ending 2026-04-30, per its 10-Q filed 2026-06-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostDepreciationAmortizationAndDepletion · last filed 2026-06-11
- RAFAEL HOLDINGS, INC. cost, depreciation, amortization and depletion for the quarter ending 2026-04-30 was $48.00K, a 22.58% decline year-over-year.
- RAFAEL HOLDINGS, INC. cost, depreciation, amortization and depletion for the quarter ending 2026-01-31 was $55.00K, a 38.89% decline year-over-year.
- RAFAEL HOLDINGS, INC. cost, depreciation, amortization and depletion for the quarter ending 2025-04-30 was $62.00K.
- RAFAEL HOLDINGS, INC. cost, depreciation, amortization and depletion for the quarter ending 2025-01-31 was $90.00K.
| Period end | Cost, Depreciation, Amortization and Depletion 3 month | Cost, Depreciation, Amortization and Depletion 6 month | Cost, Depreciation, Amortization and Depletion 9 month |
|---|---|---|---|
| 2026-04-30 | $48.00K 10-Q · filed 2026-06-11 | $103.00K derived: sum of 2 quarters · filed 2026-06-11 | $153.00K 10-Q · filed 2026-06-11 |
| 2026-01-31 | $55.00K 10-Q · filed 2026-03-16 | $105.00K 10-Q · filed 2026-03-16 | |
| 2025-04-30 | $62.00K 10-Q · filed 2026-06-11 | $152.00K derived: sum of 2 quarters · filed 2026-06-11 | $238.00K 10-Q · filed 2026-06-11 |
| 2025-01-31 | $90.00K 10-Q · filed 2026-03-16 | $176.00K 10-Q · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |